Education
About Us
Working with TipRanks
Follow Us
Lupin Limited (IN:LUPIN)
:LUPIN
LUPIN Stock Chart & Stats
₹1938.85
-₹105.50(-4.47%)
At close: 4:00 PM EST
₹1938.85
-₹105.50(-4.47%)
Day’s Range― - ―
52-Week Range₹1,774.00 - ₹2,261.95
Previous CloseN/A
Volume1.35M
Average Volume (3M)25.39K
Market Cap
₹1.02T
Enterprise Value₹1.05T
Total Cash (Recent Filing)₹29.90B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)21.9
Beta0.73
Next Earnings
May 12, 2026EPS Estimate
24.77Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)33.40
Shares Outstanding456,967,960
10 Day Avg. Volume23,417
30 Day Avg. Volume25,387
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)5.20
Price to Sales (P/S)3.94
P/FCF Ratio67.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,460.00Price Target Upside26.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained double-digit revenue growth (12.9% y/y) indicates expanding product uptake and geographic penetration. Over 2-6 months this underpins durable top-line momentum, supports reinvestment in R&D and commercial expansion, and reduces reliance on one-off product wins.
Strong Profitability & MarginsHigh gross and operating margins demonstrate persistent cost control and pricing power across portfolios. These margins create a durable earnings buffer against cyclical pressures, enabling steady internal funding for capex, R&D and brand investments over the medium term.
Solid Balance Sheet & LeverageModerate leverage and a healthy equity ratio provide financial flexibility for capital allocation and downside protection. A strong ROE near 19% signals efficient equity use, supporting sustainable returns and capacity to pursue bolt-on investments or withstand market stress.
Bears Say
Weak Free Cash FlowA sharp drop in free cash flow and low FCF-to-net-income ratio indicate weaker cash conversion of earnings. This constrains internally funded growth, dividend capacity and M&A optionality; over months this can pressure strategic flexibility if not reversed.
Reliance On U.S. GenericsMaterial exposure to U.S. generics means revenues hinge on patent cliffs, regulatory approvals and intense pricing/tender competition. This structural dependence raises medium-term revenue volatility and margin compression risk if market share or pricing weakens.
Suboptimal Cash Conversion MetricsOperating cash roughly tracks earnings but conversion shortfalls remain. Persistent gaps between profitability and free cash flow can limit sustainable capital returns and reinvestment, increasing sensitivity to working capital swings and external financing needs.
Lupin Limited News
LUPIN FAQ
What was Lupin Limited’s price range in the past 12 months?
Lupin Limited lowest stock price was ₹1774.00 and its highest was ₹2261.95 in the past 12 months.
What is Lupin Limited’s market cap?
Lupin Limited’s market cap is ₹1.02T.
When is Lupin Limited’s upcoming earnings report date?
Lupin Limited’s upcoming earnings report date is May 12, 2026 which is in 78 days.
How were Lupin Limited’s earnings last quarter?
Lupin Limited released its earnings results on Feb 12, 2026. The company reported ₹33.4 earnings per share for the quarter, beating the consensus estimate of ₹27.566 by ₹5.834.
Is Lupin Limited overvalued?
According to Wall Street analysts Lupin Limited’s price is currently Undervalued.
Does Lupin Limited pay dividends?
Lupin Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.57%. See more information on Lupin Limited dividends here
What is Lupin Limited’s EPS estimate?
Lupin Limited’s EPS estimate is 24.77.
How many shares outstanding does Lupin Limited have?
Lupin Limited has 456,967,960 shares outstanding.
What happened to Lupin Limited’s price movement after its last earnings report?
Lupin Limited reported an EPS of ₹33.4 in its last earnings report, beating expectations of ₹27.566. Following the earnings report the stock price went up 0.066%.
Which hedge fund is a major shareholder of Lupin Limited?
Currently, no hedge funds are holding shares in IN:LUPIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lupin Limited
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
LUPIN Stock 12 Month Forecast
Average Price Target
₹2,460.00
▲(26.88% Upside)
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―